Allogene Therapeutics, Inc. (ALLO) Stock Price & Analysis
Allogene Therapeutics, Inc. (ALLO) closed at USD 1.25 on Thursday, October 29, 2026, down 3.85% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 1.3; the Oct 29, 2026 session ranged USD 1.25–1.38 on volume of 7,706,522 shares. Market capitalization is $431.86M, with a 52-week range of USD 1.04–4.46 (NMS). Source: Nexqual, retrieved October 29, 2026 at 23:43 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ALLO.md
Key facts (ALLO)
- Analysts: Buy (mean 1.83 on a 1–5 scale) (12 analysts), mean target USD 9 (range 4–14).
- Total return with dividends: 1Y +3.3% vs S&P 500 +14.4%; 5Y -92.8% vs S&P 500 +79.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.14, revenue estimate $2K. All companies reporting that day: https://nexqual.com/earnings/2026-11-05
- Dividend: ALLO paid no cash dividend in the last five years.
- Short interest: 17.11% of float (as of 2026-10-15), 9.1 days to cover.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ALLO)
P/B 1.0x · FCF yield -24.14% · Earnings yield -38.94%
Analysts (ALLO)
Consensus Buy (mean 1.83 on a 1–5 scale), 12 analysts; mean target USD 9 (low 4, high 14).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-17 | Citizens | Reiterated | Market Outperform | $6 |
Total return (dividends reinvested) (ALLO)
| 1Y (from 2025-10-30) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +3.3% | -92.8% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | +3.3% | -40.8% |
| Volatility (annualized) | 82.8% | 76.3% |
| Max drawdown | -60.5% (Apr 2026→Oct 2026) | -94.8% (Nov 2021→Aug 2025) |
Dividends (ALLO)
ALLO paid no cash dividend in the last five years.
Short interest (ALLO)
53,405,256 shares sold short, 17.11% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 59,600,117 shares (-10.4%). Days to cover: 9.1 (short shares ÷ average daily volume).
ALLO earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.13 | −$0.15 | Beat +13.3% | — |
| — | Quarter ended Mar 31, 2026 | −$0.18 | −$0.18 | In line | — |
| — | Quarter ended Dec 31, 2025 | −$0.17 | −$0.22 | Beat +22.7% | — |
| — | Quarter ended Sep 30, 2025 | −$0.19 | −$0.23 | Beat +17.4% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
Companies that name ALLO in their SEC reports
| Relationship to ALLO | Company | Filing | Sentence |
|---|---|---|---|
| partner | Cellectis S.A. (CLLS) | 20-F Mar 20, 2026 | “We have entered into licensing or collaboration agreements with partners, such as Allogene, Servier and AstraZeneca under which our partners have or have the right to obtain exclusive development and commercialization rights with respect to certain product candidates.” |
ALLO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.14 | $-0.14 | $0.00 | $2,220 | 6 |
| Next quarter (ends Dec 2026) | $-0.14 | $-0.15 | +$0.01 | $2,220 | 6 |
| Current fiscal year (ends Dec 2026) | $-0.58 | $-0.61 | +$0.03 | $3.7M | 6 |
| Next fiscal year (ends Dec 2027) | $-0.62 | $-0.68 | +$0.07 | $12.1M | 5 |
ALLO options: expected move
Options price a move of about ±24.6% (±$0.33) by Nov 20, 2026, which includes earnings on Nov 5, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 22 | 107.9% | ±24.6% |
| Feb 19, 2027 | 113 | 81.0% | ±39.8% |
| May 21, 2027 | 204 | 159.4% | ±51.1% |
30-day implied volatility 85.2% vs 45.7% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 23:43 UTC)
| Price | USD 1.25 |
|---|---|
| Change | ▼ 3.85% (down) |
| Previous Close | USD 1.3 |
| Open | USD 1.33 |
| Day Range | USD 1.25 – 1.38 |
| 52-Week Range | USD 1.04 – 4.46 |
| Volume | 7,706,522 shares |
| Market Cap | $431.86M |
| Exchange | NMS |
Technical Analysis (ALLO)
Nexqual's technical model rates ALLO "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 23:43 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 31.95 (neutral) |
| vs SMA50 | Below (USD 1.64) |
| MACD | -0.11 (negative) |
Analyst Ratings (ALLO)
Wall Street analysts rate ALLO "Buy" based on 12 analysts, with a mean price target of USD 9 (range USD 4–14), per Nexqual as of October 29, 2026 at 23:43 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 9 |
| High Target | USD 14 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 11 / 1 / 0 |
Earnings (ALLO)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.14 |
| Revenue Estimate | $2,220 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.13 vs est -0.15 ▲ beat |
| 2026-03-31 | USD -0.18 vs est -0.18 ▲ beat |
| 2025-12-31 | USD -0.17 vs est -0.22 ▲ beat |
| 2025-09-30 | USD -0.19 vs est -0.23 ▲ beat |
Source: Nexqual, October 29, 2026 at 23:43 UTC.
Financials & Fundamentals (ALLO)
| Total Revenue | $4.64M |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -1011.21% |
| Profit Margin | +0.00% |
| ROE | -42.39% |
| Debt / Equity | 0.18 |
| Current Ratio | 10.72 |
| Total Cash | $332.60M |
| Total Debt | $79.01M |
Source: Nexqual, October 29, 2026 at 23:43 UTC.
Financial Health Score (ALLO)
Nexqual rates Allogene Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 23:43 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $333M cash vs $79M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$149M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -42%, ROA -22.1% |
Ownership (ALLO)
| Insider Ownership | +11.02% |
|---|---|
| Institutional Ownership | +82.83% |
| Shares Outstanding | 345.49M |
| Float | 281.85M |
| Short % of Float | +17.11% |
Source: Nexqual, October 29, 2026 at 23:43 UTC.
Leadership (ALLO)
Allogene Therapeutics, Inc. is led by Zachary J. Roberts, President, CEO & Director, per Nexqual as of October 29, 2026 at 23:43 UTC.
| President, CEO & Director | Zachary J. Roberts |
|---|---|
| Co-Founder & Executive Chairman | Arie S. Belldegrun F.A.C.S. |
| Co-Founder & Director | Joshua A. Kazam |
| Co-Founder & Director | David D. Chang |
| Executive VP & CFO | Geoffrey M. Parker |
Major Backers & Investors (ALLO)
Notable institutional backers of Allogene Therapeutics, Inc. include Frazier Life Sciences Management, L.P. , Pfizer Inc, TPG GP A, LLC, according to Nexqual as of October 29, 2026 at 23:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 6.5% |
| Pfizer Inc | 6.38% |
| TPG GP A, LLC | 5.42% |
| Sio Capital Management, LLC | 3.86% |
| Primecap Management Company | 3.8% |
| Fidelity | 3.75% |
| FMR, LLC | 3.48% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.73% |
| State Street | 5.51% |
| Vanguard Group | 3.52% |
Source: Nexqual, October 29, 2026 at 23:43 UTC.
From Allogene Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Multiple autologous anti-CD19 CAR T therapies have shown promising results and have been approved by the FDA as therapies in multiple blood cancers, including relapsed/refractory (R/R) LBCL, as further described below under "—Competition".
- We believe a critical component to our success will be to leverage and expand our proprietary manufacturing know-how, expertise and capacity.
- Using our proprietary allogeneic CAR T cell platform, we are researching and developing multiple product candidates for the treatment of blood cancers, solid tumors and autoimmune diseases.
- The updated results continue to demonstrate the potential of an allogeneic CAR T product candidate to treat CD70-expressing RCC and highlight the impact of our proprietary Dagger® technology in enabling robust CAR T-cell expansion and persistence in solid tumors.
Partnerships
- In February 2025, we entered into an Amended and Restated Strategic Collaboration Agreement with Foresight Diagnostics which expands our collaboration to enable the development of Foresight Diagnostics' CLARITYTM MRD assay as a companion diagnostic in the EU, UK, Canada and Australia in support of Allogene's clinical development of cema-cel.
- On May 10, 2024, we entered into an Amendment and Settlement Agreement (the Servier Amendment) with Servier which restructures our relationship under the Servier Agreement.
Legal & Regulatory Risks (Item 1A, quoted)
- The FDA and other comparable foreign regulatory approval processes are lengthy, time-consuming, and subject to change and we may experience significant delays in the clinical development and regulatory approval of our product candidates.
- The FDA or comparable foreign regulatory authorities may disagree with our regulatory plan and we may fail to obtain regulatory approval of our CAR T cell product candidates.
- We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.
- The use of engineered T cells as a potential cancer treatment is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 317.33 | ▼ 0.45% |
| ORKA | Oruka Therapeutics, Inc. | USD 96.65 | ▲ 0.71% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 93.07 | ▲ 1.2% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.39 | ▼ 1.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.45 | ▼ 0.04% |
| ABVX | Abivax SA | USD 89.06 | ▼ 0.87% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 23:43 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt